帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Regulatory B cell-related gene signature predicts prognosis and immune landscape in head and neck squamous cell carcinoma.
Regulatory B cell-related gene signature predicts prognosis and immune landscape in head and neck squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Breg 相关基因特征为 HNSCC 患者提供了一种有效的预后工具,反映了免疫景观和 TMB,并可能指导个性化治疗方法,如免疫治疗。
调节性B细胞(Bregs)在多种癌症中对于调控免疫反应和促进免疫耐受至关重要;然而,它们在头颈部鳞状细胞癌(HNSCC)中的作用尚不清楚。本研究探讨了Breg相关基因在HNSCC中的功能及其可能的预后和治疗意义。
使用癌症基因组图谱(TCGA)-HNSCC训练队列,通过应用共识聚类、单因素Cox回归、最小绝对收缩和选择算子(LASSO)Cox回归以及多因素Cox回归分析,建立了Breg相关基因的预后特征。使用来自TCGA和基因表达综合数据库(GEO)的验证队列评估模型的稳健性。本研究探讨了该特征与若干临床病理特征、免疫检查点表达、肿瘤突变负荷(TMB)以及药物敏感性之间的关联。使用加权基因共表达网络分析(WGCNA)和基因集富集分析(GSEA)检查了潜在机制。此外,使用包括ESTIMATE在内的多种技术评估免疫浸润。进行了功能实验和转录组测序,以研究氧化低密度脂蛋白受体1(OLR1)基因的作用。
该分析确定了一个与Breg相关的八基因预后特征,该特征在多个队列中均显示出强大的预测能力。高风险患者的生存率显著较差,免疫细胞浸润减少,免疫分子表达降低。通过将风险评分与TMB或临床病理特征相结合,预后准确性得到进一步提高。功能分析揭示了与免疫相关通路的强烈关联。此外,该特征被报道为预测免疫治疗反应和药物敏感性的潜在生物标志物。进一步发现,该特征中最关键的基因OLR1在HNSCC中具有致癌性,并与免疫逃逸相关。
Regulatory B cells (Bregs) are critical in regulating immune responses and fostering immune tolerance in various cancers; however, their role in head and neck squamous cell carcinoma (HNSCC) is unclear. This study examined the function of Breg-related genes in HNSCC and their possible prognostic and therapeutic implications.
The Cancer Genome Atlas (TCGA)-HNSCC training cohort was used to establish a prognostic signature for Breg-related genes by applying consensus clustering, univariate Cox regression, least absolute shrinkage and selection operator (LASSO) Cox regression, and multivariate Cox regression analyses. Validation cohorts from the TCGA and Gene Expression Omnibus (GEO) databases were used to assess the robustness of the model. This study investigated the associations among the signature and several clinicopathological features, expression of immune checkpoints, tumor mutation burden (TMB), and sensitivity to pharmacological agents. The underlying mechanisms were examined using weighted gene co-expression network analysis (WGCNA) and gene set enrichment analysis (GSEA). Additionally, various techniques, including ESTIMATE, were used to assess immune infiltration. Functional experiments and transcriptome sequencing were conducted to investigate the role of oxidized low-density lipoprotein receptor 1 (OLR1) gene.
The analysis identified an eight-gene Breg-related prognostic signature that demonstrated robust predictive power across cohorts. High-risk patients exhibited significantly poorer survival, reduced immune cell infiltration, and lower immune molecule expression. The prognostic accuracy was further improved by integrating the risk score with TMB or clinicopathological features. Functional analyses revealed strong associations with immune-related pathways. Moreover, the signature was reported as a potential biomarker for predicting immunotherapy response and drug sensitivity. Furthermore, OLR1, the most essential gene of the signature, was found to be oncogenic and linked to immune evasion in HNSCC.
The Breg-related gene signature provides an effective prognostic tool for patients with HNSCC, reflects the immune landscape and TMB, and may direct personalized therapeutic approaches, such as immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。